Momenta Pharmaceuticals Announces Jury Verdict in Enoxaparin Sodium Injection Patent Litigation Against Amphastar
July 21 2017 - 1:17PM
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) today announced that
the jury in the District Court for the District of Massachusetts in
Boston has issued its verdict finding that the Company’s U.S.
Patent No. 7,575,886, covering methods for the manufacturing of
generic LOVENOX® (Enoxaparin Sodium Injection), was infringed, but
invalid and unenforceable.
“We are disappointed in the jury’s verdict and
believe the facts and the law do not support these findings. We are
considering all available legal options to overturn the verdict,
including post-trial motions and appeals,” said Craig Wheeler,
President and Chief Executive Officer of Momenta. “We continue to
believe in the importance of investing in innovative techniques for
bringing products to market and protecting those innovations from
unauthorized use.”
Formal judgment has not yet been entered.
About Momenta
Momenta Pharmaceuticals is a biotechnology
company specializing in the detailed structural and functional
analysis of complex drugs and is headquartered in Cambridge,
MA. Momenta is applying its technology to the development of
generic versions of complex drugs, biosimilar and potentially
interchangeable biologics, and to the discovery and development of
novel therapeutics for autoimmune indications.
To receive additional information about Momenta,
please visit the website at www.momentapharma.com, which does not
form a part of this press release. The company’s logo, trademarks,
and service marks are the property of Momenta Pharmaceuticals, Inc.
All other trade names, trademarks, or service marks are property of
their respective owners.
Forward Looking Statements
Statements in this press release regarding
management's future expectations, beliefs, intentions, goals,
strategies, plans or prospects, including statements relating to
its beliefs and intentions related to the jury’s findings, the
importance of investing in innovative techniques, and our
considering all available legal options to overturn the
verdict are forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of
1995. Forward-looking statements can be identified by
terminology such as "believe," "continue," "is considering,"
"will," or similar terms, variations of such terms or the negative
of those terms. Such forward-looking statements involve known
and unknown risks, uncertainties and other factors referred to in
the Company's Quarterly Report on Form 10-Q for the month
ended March 31, 2017 filed with the Securities and
Exchange Commission under the section "Risk Factors," as well
as other documents that may be filed by Momenta from time to time
with the Securities and Exchange Commission. As a result
of such risks, uncertainties and factors, the Company's actual
results may differ materially from any future results, performance
or achievements discussed in or implied by the forward-looking
statements contained herein. Momenta is providing the
information in this press release as of this date and assumes no
obligations to update the information included in this press
release or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Investor Relations:
Sarah Carmody
Momenta Pharmaceuticals
1-617-395-5189
IR@momentapharma.com
Media Relations:
Karen Sharma
MacDougall Biomedical Communications
1-781-235-3060
Momenta@macbiocom.com
Momenta Pharmaceuticals (NASDAQ:MNTA)
Historical Stock Chart
From Apr 2024 to May 2024
Momenta Pharmaceuticals (NASDAQ:MNTA)
Historical Stock Chart
From May 2023 to May 2024